Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Huntington Disease · Alzheimer Disease · VYGR

Voyager Therapeutics

Voyager Therapeutics patent portfolio — 31 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Lexington, USA HQ
2014 Founded
168 Employees
Public company Type
VYGR · NYSE Ticker
Company details
Status
Public
HQ
Lexington, USA
Founded
2014
Employees
168
Programs
4
Drugs
4
Patents
31
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Voyager Therapeutics patents

31 pharmaceutical patents indexed for Voyager Therapeutics. 0 expire within 24 months.

Voyager Therapeutics has 31 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

31 patents

Patent portfolio

  1. US 12419969

    AAV capsid variants and uses thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12319929

    Compositions and methods for the treatment of Parkinson's disease

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12305189

    Compositions and methods for delivery of AAV

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12296025

    AAV capsid variants and uses thereof

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12291565

    Tau binding compounds

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12281321

    Frataxin expression constructs having engineered promoters and methods of use thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12252703

    Closed-ended linear duplex DNA for non-viral gene transfer

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12146150

    Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12129476

    Methods for measuring the potency of AADC viral vectors

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12123002

    Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12116589

    Treatment of amyotrophic lateral sclerosis (ALS)

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12084659

    Modulatory polynucleotides

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11975056

    AADC polynucleotides for the treatment of Parkinson's disease

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11951121

    Compositions and methods for treating Huntington's disease

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11931375

    Treatment of amyotrophic lateral sclerosis (ALS)

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11859200

    AAV capsids with increased tropism to brain tissue

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11759506

    AADC polynucleotides for the treatment of Parkinson's disease

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11752181

    Compositions and methods of treating Huntington's disease

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11603542

    Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11542506

    Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11512327

    Compositions and methods for delivery of AAV

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11434502

    Treatment of amyotrophic lateral sclerosis (ALS)

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11326182

    Compositions for the treatment of disease

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11299751

    Compositions for the treatment of disease

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11193129

    Modulatory polynucleotides

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11066679

    Closed-ended linear duplex DNA for non-viral gene transfer

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11027000

    AADC polynucleotides for the treatment of Parkinson's disease

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10920227

    Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

    Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10597660

    Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10584337

    Modulatory polynucleotides

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10335466

    AADC polynucleotides for the treatment of parkinson's disease

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Voyager Therapeutics have?

31 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Voyager Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.